Skip to main content

Research Repository

Advanced Search

All Outputs (6)

Improving the understanding and management of back pain in older adults: the BOOST research programme including RCT and OPAL cohort (2023)
Report
Williamson, E., Sanchez-Santos, M. T., Marian, I. R., Maredza, M., Srikesavan, C., Garrett, A., Morris, A., Boniface, G., Dutton, S. J., Griffiths, F., Collins, G. S., Petrou, S., Bruce, J., Fairbank, J., Hansen, Z., Barker, K., Hutchinson, C., Mallen, C., Ward, L., Gagen, R., …Lamb, S. E. (2023). Improving the understanding and management of back pain in older adults: the BOOST research programme including RCT and OPAL cohort. NIHR

Background Back pain frequently affects older people. Knowledge about back pain in older people and evidence to inform clinical care was lacking, particularly for older people with neurogenic claudication due to spinal stenosis, which is a debilitati... Read More about Improving the understanding and management of back pain in older adults: the BOOST research programme including RCT and OPAL cohort.

"If we use the strength of diversity among researchers we can only improve the quality and impact of our research": Issues of equality, diversity, inclusion, and transparency in the process of applying for research funding (2023)
Report
Bell, A., Biglino, G., Blackburn, M., Brown, J., Bruce, R., Buckley Woods, H., Burnett, C., Clift, K., Couzin, N., Derrick, G. E., Duncan, L. J., Eyland, S., Gooberman-Hill, R., Harris, S., Jones, A. F., Jones, P., Kitou, E., Knipe, D., Maia Schlüssel, M., Meadows, A., …Verghese, V. (2023). "If we use the strength of diversity among researchers we can only improve the quality and impact of our research": Issues of equality, diversity, inclusion, and transparency in the process of applying for research funding. Elizabeth Blackwell Institute, University of Bristol, the Wellcome Trust Institutional Strategic Support Fund, MoreBrains Cooperative

This paper sets out the recommendations that have emerged from a six-month-long exploration and discussion of the processes that take place before research is submitted for funding: the 'pre-award' environment. Our work concentrated on how this envir... Read More about "If we use the strength of diversity among researchers we can only improve the quality and impact of our research": Issues of equality, diversity, inclusion, and transparency in the process of applying for research funding.

Digital health and inpatient palliative care: a cohort-controlled study (2023)
Report
Singh, B. M., Kumari-Dewat, N., Ryder, A., Parry, E., Klaire, V., Matthews, D., Bennion, G., Jennens, H., Ritzenthaler, B. M. E., Rayner, S., Shears, J., Ahmed, K., Sidhu, M., Viswanath, A., & Warren, K. (2023). Digital health and inpatient palliative care: a cohort-controlled study. BMJ

Objectives End of life has unacceptable levels of hospital admission and death. We aimed to determine the association of a novel digital specific system (Proactive Risk-Based and Data-Driven Assessment of Patients at the End of Life, PRADA) to modify... Read More about Digital health and inpatient palliative care: a cohort-controlled study.

One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT (2023)
Report
Brunt, A., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Bloomfield, D. J., Chan, C., Cleator, S., Coles, C. E., Donovan, E., Fleming, H., Glynn, D., Goodman, A., Griffin, S., Hopwood, P., Kirby, A. M., Kirwan, C. C., Nabi, Z., Patel, J., Sawyer, E., Somaiah, N., …Bliss, J. M. (2023). One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT

FAST-Forward aimed to identify a 5-fraction schedule of adjuvant radiotherapy delivered in 1 week that was non-inferior in terms of local cancer control and as safe as the standard 15-fraction regimen after primary surgery for early breast cancer. Pu... Read More about One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.